J. Atkins

Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study

P. A. Philip, Jacqueline Benedetti, Cecilia M. Fenoglio‐Preiser et al. · Journal of Clinical Oncology · 2007 · 187 citations

Medicine, Oncology, Pharmacology +17

Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer

Silvia Novello, Giorgio V. Scagliotti, Rafael Rosell et al. · British Journal of Cancer · 2009 · 132 citations · Full text

Medicine, Oncology, Pharmacology +15

Calgb/Swog 80405: Phase III Trial of Irinotecan/5-Fu/Leucovorin (Folfiri) or Oxaliplatin/5-Fu/Leucovorin (Mfolfox6) with Bevacizumab (Bv) or Cetuximab (Cet) for Patients (Pts) with Expanded Ras Analyses Untreated Metastatic Adenocarcinoma of the Colon Or Rectum (Mcrc)

Heinz‐Josef Lenz, Donna Niedzwiecki, Federico Innocenti et al. · Annals of Oncology · 2014 · 110 citations

Medicine, Oncology, Pharmacology +16

A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer

G. Deplanque, Martin Demarchi, Mohamed Hebbar et al. · Annals of Oncology · 2015 · 93 citations

Medicine, Oncology, Pharmacology +11

The impact of sharing results of a randomized breast cancer clinical trial with study participants

Ann H. Partridge, Antonio C. Wolff, P. Kelly Marcom et al. · Breast Cancer Research and Treatment · 2008 · 46 citations

Public Health, Biostatistics, Oncology +13